Benjamin A. Katchman Joins Cannabis Science and Technology’s Editorial Advisory Board
Cannabis Science and Technology is pleased to announce the addition of Benjamin A. Katchman, PhD, to its editorial advisory board (EAB).
Benjamin A. Katchman, PhD
Cannabis Science and Technology is pleased to announce the addition of Benjamin A. Katchman, PhD, to its editorial advisory board (EAB).
Dr. Katchman received a B.S. in microbiology from Indiana University in 2005, then carried out graduate research with Professor Douglas F. Lake at Arizona State University where he was the first to identify QSOX1 as a proto-oncogene and novel tumor biomarker resulting in more than $2M in funding and multiple patents. Katchman performed his postdoctoral research with Professors Karen S. Anderson and Joshua LaBaer where he designed novel high-density protein microarrays and novel clinical and point of care diagnostics utilizing flexible organic light-emitting diode (OLED)-based electronics resulting in more than $15M in funding, multiple patents, and high-impact publications.
Dr. Katchman is a Principal Scientist at PathogenDx where he leads the research and development of sample preparation and assay development. PathogenDx is a Scottsdale, Arizona based company that provides disruptive DNA-based pathogen testing technology and solutions for the cannabis, botanical, food, and agricultural industries.
Previously, Dr. Katchman spent 20 years working with various universities and small companies developing novel nucleic acid and proteomic approaches for biomarker discovery and molecular diagnostics. This includes the development of plate-based and microarray-based diagnostic systems for use in clinical laboratories and point-of-care diagnostics for Arizona State University, FlexBioTech, Inc., and Eccrine Systems, Inc.
Prior to joining PathogenDx, Dr. Katchman was a Principle Investigator at Eccrine Systems, Inc., where he led all clinical research, regulatory pathway implementation, assay development, and biomarker studies. He was the co-founder of FlexBioTech, Inc., where he led the development of novel OLED-based molecular diagnostic assay platforms.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
